Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices
- PMID: 38668035
- PMCID: PMC11049204
- DOI: 10.3390/curroncol31040132
Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices
Abstract
This study aims to evaluate the clinical outcome of stereotactic radiosurgery as the sole treatment for brain metastases and to assess prognostic factors influencing survival. A total of 108 consecutive patients with 213 metastases were retrospectively analyzed. Treatment was determined with close-meshed MRI follow-up. Various prognostic factors were assessed, and several prognostic indices were compared regarding their reliability to estimate overall survival. Median overall survival was 15 months; one-year overall survival was 50.5%. Both one- and two-year local controls were 90.9%. The rate of new metastases after SRS was 49.1%. Multivariate analysis of prognostic factors revealed that the presence of extracranial metastases, male sex, lower KPI, and progressive extracranial disease were significant risk factors for decreased survival. Of all evaluated prognostic indices, the Basic Score for Brain Metastases (BSBMs) showed the best correlation with overall survival. A substantial survival advantage was found for female patients after SRS when compared to male patients (18 versus 9 months, p = 0.003). SRS of brain metastasis is a safe and effective treatment option when frequent monitoring for new metastases with MRI is performed. Common prognostic scores lack reliable estimation of survival times. Female sex should be considered as an additional independent positive prognostic factor influencing survival.
Keywords: brain metastases; outcome; prognosis; prognostic scores; radiosurgery; sex differences.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11049204/bin/curroncol-31-00132-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11049204/bin/curroncol-31-00132-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11049204/bin/curroncol-31-00132-g003.gif)
Similar articles
-
Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery.J Neurosurg. 2018 Jan;128(1):14-22. doi: 10.3171/2016.9.JNS161011. Epub 2017 Jan 20. J Neurosurg. 2018. PMID: 28106495
-
Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.J Neurosurg. 2015 Nov;123(5):1261-7. doi: 10.3171/2014.12.JNS141919. Epub 2015 Jul 3. J Neurosurg. 2015. PMID: 26140482
-
Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone.J Neurosurg. 2012 Dec;117 Suppl(0):38-44. doi: 10.3171/2012.3.GKS1289. J Neurosurg. 2012. PMID: 23205787 Free PMC article.
-
Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.J Neurosurg. 2018 Jul;129(1):71-83. doi: 10.3171/2017.2.JNS161659. Epub 2017 Aug 18. J Neurosurg. 2018. PMID: 28820304
-
Activity of extracranial metastases as a prognostic factor influencing survival after radiosurgery of brain metastases.J Cancer Res Clin Oncol. 2000 Aug;126(8):475-80. doi: 10.1007/s004320000126. J Cancer Res Clin Oncol. 2000. PMID: 10961391 Review.
References
-
- Linskey M.E., Andrews D.W., Asher A.L., Burri S.H., Kondziolka D., Robinson P.D., Ammirati M., Cobbs C.S., Gaspar L.E., Loeffler J.S., et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010;96:45–68. doi: 10.1007/s11060-009-0073-4. - DOI - PMC - PubMed
-
- Schiff D., Messersmith H., Brastianos P.K., Brown P.D., Burri S., Dunn I.F., Gaspar L.E., Gondi V., Jordan J.T., Maues J., et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2022;40:JCO2200333. doi: 10.1200/JCO.22.00333. - DOI - PubMed
-
- Soffietti R., Kocher M., Abacioglu U.M., Villa S., Fauchon F., Baumert B.G., Fariselli L., Tzuk-Shina T., Kortmann R.D., Carrie C., et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J. Clin. Oncol. 2013;31:65–72. doi: 10.1200/JCO.2011.41.0639. - DOI - PubMed
-
- Yamamoto M., Serizawa T., Shuto T., Akabane A., Higuchi Y., Kawagishi J., Yamanaka K., Sato Y., Jokura H., Yomo S., et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol. 2014;15:387–395. doi: 10.1016/S1470-2045(14)70061-0. - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical